| NCT03632798 | III | Recurrent ovarian cancer | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | MS, WV | View Drugs | |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03949283 | III | Platinum resistant or refractory ovarian cancer | Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | AZ, CA, LA, OH, OK, PA, WV | View Drugs | |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04209855 | III | Platinum resistant or refractory FRalpha+ high grade serous ovarian cancer, excluding primary platinum refractory | MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | AL, AK, AZ, CA, CO, CT, FL, GA, IL, IN, KY, LA, MD, MA, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WV | View Drugs | View Results |
Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials |
|
|
| NCT03398655 | III | Platinum resistant or refractory ovarian cancer, excluding primary platinum refractory | A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer | AL, AZ, CA, CT, FL, GA, IL, IN, KS, KY, LA, MD, MA, MI, NH, NJ, NM, NY, NC, ND, OH, OK, PA, SC, SD, TX, VT, WA, WI | View Drugs | View Results |
Ofranergene obadenovec | VB-111 | Endothelin promoter-apoptotic receptor gene therapy | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04729608 | III | Platinum resistant or refractory high grade serous ovarian cancer, excluding primary platinum refractory | A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Contact research study staff | View Drugs | View Results |
AVB-S6-500 | AVB-500 | GAS6 antagonist | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03940196 | III | Recurrent ovarian cancer with ≤2 prior therapies for platinum resistant disease, excluding primary platinum refractory | ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer | AZ, CA, CO, FL, GA, IA, KY, MD, MA, MN, MO, NE, NV, NJ, NC, OH, OR, PA, RI, SD, TX, VA, WA | View Drugs | View Results |
Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | TTfields | NovoTTF-100L(O) | Microtubule destabilizer/mitotic inhibitor | Clinical Trials |
|
|
| NCT04296890 | III | Platinum resistant or refractory FRalpha+ ovarian cancer with prior bevacizumab; excluding primary platinum refractory | SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | AZ, CA, CO, FL, GA, IL, IN, KS, KY, LA, MD, MA, MO, NV, NJ, NY, TN, TX, WA, WI | View Drugs | View Results |
Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials |
|
|
| NCT04729387 | III | Platinum resistant or refractory gBRCA WT high grade serous or endometrioid ovarian cancer | EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer | Contact research study staff | View Drugs | View Results |
Alpelisib | PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray | PI3K alpha inhibitor | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02419417 | IIa | Platinum resistant or refractory ovarian cancer with BRCA1/2 mutations | A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies | MA, OH, SC | View Drugs | View Results |
BMS-986158 | BET inhibitor BMS-986158 | BET inhibitor | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02584478 | IIa | Recurrent ovarian cancer | A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | CA, FL, LA, TX | View Drugs | View Results |
Anlotinib | Catequentinib, AL3818 | VEGFR2/3 kinase inhibitor | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02502266 | II/III | Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer | A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) | AL, AK, AR, CA, CO, CT, DE, DC, FL, GA, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI | View Drugs | View Results |
Cediranib | AZD2171, Cediranib maleate, Recentin | VEGFR1-3 kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02272998 | II | Advanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations | Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1) | OH | View Drugs | |
Ponatinib | multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534 | Multi-targeted kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03909152 | II | Recurrent PR+ low grade serous or granulosa cell ovarian cancer | Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer | NJ, NY | View Drugs | View Results |
Onapristone ER | extended-release onapristone | PR antagonist that blocks PR activation and the associated expression of PR-responsive genes | |
|
|
| NCT03587311 | II | Platinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancer | A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer | CA, FL, IL, KS, MI, NJ, OH, TN, VA | View Drugs | View Results |
Anetumab ravtansine | Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343, BAY 94-9343 | ADC: anti-Mesothelin + microtubule destabilizer (DM4) | Clinical Trials | Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03579316 | II | Recurrent ovarian cancer with progression on or after prior PARP inhibitor | EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition | MA, TX | View Drugs | View Results |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04172597 | II | Advanced solid tumors with EGFR or ERBB2 activating mutations | A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | CA | View Drugs | View Results |
Poziotinib | NOV120101, pan-HER kinase inhibitor HM781-36B | EGFR, HER2, HER4 kinase inhibitor | |
|
|
| NCT04003623 | II | Advanced solid tumors with FGFR mutations or translocations | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208) | CA, FL, HI, IL, MD, NJ, OH, SD, TX, UT | View Drugs | View Results |
Pemigatinib | FGFR inhibitor INCB054828, INCB054828, Pemazyre | FGFR1-3 inhibitor | Approved in Other Cancers |
|
|
| NCT04233567 | II | Advanced solid tumors with FGFR alterations | A Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic Alterations | OH | View Drugs | View Results |
Infigratinib | pan FGFR Kinase Inhibitor BGJ398, BGJ398 | pan-FGFR kinase inhibitor | Clinical Trials |
|
|
| NCT02079740 | II | Advanced solid tumors with KRAS or NRAS mutations (in expansion) | An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors | MA | View Drugs | View Results |
Navitoclax | ABT-263, A-855071.0, Bcl-2 Family Protein Inhibitor ABT-263 | Bcl-2, Bcl-XL, and Bcl-w inhibitor | Clinical Trials | Trametinib | Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 | MEK1/2 inhibitor | Approved in Other Cancers |
|
|
| NCT02710253 | II | Advanced solid tumors (amenable to radiation therapy) | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | TX | View Drugs | View Results |
Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT02843165 | II | Advanced solid tumors with lesion treatable with radiation therapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | CA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Radiotherapy, Irradiation | | |
|
|
| NCT04083976 | II | Advanced solid tumors with FGFR mutations or gene fusions | A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations | AZ, CO, FL, GA, ME, MA, MI, NJ, NY, NC, OH, PA, TN, TX, WA, WI | View Drugs | View Results |
Erdafitinib | pan-FGFR tyrosine kinase inhibitor JNJ-42756493 | pan-FGFR kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03822117 | II | Advanced solid tumors with FGFR1-3 gene mutations or translocations | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | AZ, CA, FL, IL, IN, IA, KS, LA, ME, MA, MN, NV, NH, NJ, NY, NC, OK, SC, TN, TX, VA, WA, WV, WI | View Drugs | View Results |
Pemigatinib | FGFR inhibitor INCB054828, INCB054828, Pemazyre | FGFR1-3 inhibitor | Approved in Other Cancers |
|
|
| NCT03868423 | II | Advanced solid tumors with ALK or ROS1 activating genomic aberrations | Phase II Study of Brigatinib for Advanced Solid Cancers Harboring Genomic Alterations in ALK (Excluding Lung) and ROS1 Oncogenes | OH | View Drugs | View Results |
Brigatinib | AP26113, Alunbrig | ALK and EGFR kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04055649 | II | Platinum resistant or refractory ovarian cancer | Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | MI | View Drugs | View Results |
ONC201 | AKT/ERK inhibitor ONC201, TIC10 | AKT and ERK kinase inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04383210 | II | Advanced solid tumors with a NRG1 gene fusion | CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors | AZ, CA, CO, FL, IL, MA, MI, MO, NY, NC, TN, TX, VA, WA, WI | View Drugs | |
Seribantumab | SAR256212, MM-121 | ERBB3 antagonist | Clinical Trials |
|
|
| NCT02364713 | II | Platinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity) | MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer | AZ, FL, MN | View Drugs | View Results |
MV-NIS | oncolytic measles virus encoding thyroidal sodium iodide symporter | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT03310879 | II | Advanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplifications | A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | MA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03878849 | II | Recurrent ovarian cancer | Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | MA | View Drugs | View Results |
Stenoparib | PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121 | PARP inhibitor | Clinical Trials |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03284385 | II | Advanced solid tumors with SETD2 deficiency | A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies | CA, IL, KS, MD, MA, MI, NY, PA, TN, TX | View Drugs | View Results |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | Clinical Trials |
|
|
| NCT03673124 | II | Recurrent low grade serous ovarian cancer | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum | CA, FL, GA, IL, IN, MN, NH, NJ, NM, OH, OK, PA, RI, TX | View Drugs | View Results |
Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04469764 | II | Recurrent ovarian cancer with CCND1-3 or CDK4/6 AMP or CDKN2A alterations | An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer | CA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Anastrozole | Arimidex | Aromatase inhibitor | | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04488003 | II | Advanced solid tumors with atypical BRAF or MEK alterations | A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations | DE, MN, NC, TX, WI | View Drugs | View Results |
Ulixertinib | BVD-523, ERK inhibitor BVD-523 | ERK inhibitor | Clinical Trials |
|
|
| NCT03994796 | II | Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations | Genomically-Guided Treatment Trial in Brain Metastases | AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NM, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Paxalisib | RG7666, PI3K inhibitor GDC-0084, GDC-0084 | PI3K/mTOR inhibitor | |
|
|
| NCT02834013 | II | Advanced ovarian small cell cancer | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04504942 | II | Advanced CCR5+ solid tumors - subcutaneous injection of leronlimab with standard-of-care chemotherapy | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | CA | View Drugs | View Results |
Leronlimab | anti-CCR5 monoclonal antibody PRO 140 | Modulates the tumor microenvironment and blocks tumor angiogenesis | Clinical Trials |
|
|
| NCT04534283 | II | Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1 | A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1. | IN | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | LY3214996 | | ERK inhibitor | Clinical Trials |
|
|
| NCT04482309 | II | Advanced HER2+ solid tumors | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) | CA, IL, IN, MA, MI, MO, NY, NC, OH, TN, TX, VA, WA | View Drugs | |
Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT04564027 | II | Advanced solid tumors with ATM mutations | A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE) | CA, FL, IN, MD, MI, NV, NY, PA, SC | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials |
|
|
| NCT04239014 | II | Recurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapy | A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment | AK, CA, CT, FL, GA, KY, LA, MI, MN, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TX, VA, WA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04171700 | II | Advanced solid tumors with mutations in BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B, RAD51C or RAD51D, no prior PARP inhibitor | A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes | CA, FL, IL, IA, MA, MN, NY, OH, OK, PA, TN, WA | View Drugs | View Results |
|
|
| NCT03212274 | II | Advanced solid tumors with IDH1 or IDH2 mutations, no prior PARP inhibitor | A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | CA, CT, FL, GA, KS, KY, MD, MA, MO, NH, NJ, NY, NC, OH, OK, PA, TN, TX, WI | View Drugs | |
|
|
| NCT02628067 | II | Advanced solid tumors with high MSI or high TMB | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | CA, FL, MD, MA, NJ, TX | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03797326 | II | Advanced solid tumors (in ovarian expansion) | A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005) | CA, FL, NJ, NY, SD, TN, WI | View Drugs | View Results |
Lenvatinib | E7080, ER-203492-00, Lenvima, MK-7902 | VEGFR1-3 kinase inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04374630 | II | Platinum resistant ovarian cancer (must either have received or be ineligible for prior bevacizumab and/or PARP inhibitor) | An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer | KY, MA, NJ, OH | View Drugs | View Results |
Afuresertib | GSK2110183 | Akt inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03668119 | II | Advanced solid tumors with high TMB | A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | CA, CO, MN, NY, NC, OR, TX | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03355976 | II | Recurrent clear cell ovarian cancer | BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | RI | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03570619 | II | Advanced solid tumors with CDK12 alterations | IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | CA, FL, MD, MI, MO, NY | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03113487 | II | Platinum resistant or refractory ovarian cancer | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | CA | View Drugs | View Results |
p53MVA | Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53 | Immune response against p53 tumor antigen | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | KY | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT04056910 | II | Advanced solid tumors with IDH1 mutations | Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors | PA | View Drugs | |
Ivosidenib | AG-120 | IDH1 inhibitor | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03026062 | II | Platinum resistant or refractory clear cell ovarian cancer | Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer | TX | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT03734692 | II | Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | PA | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rintatolimod | Atvogen | TLR3 agonist and immune cell stimulator | Approved in Other Indications |
|
|
| NCT03935893 | II | Advanced solid tumors | A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers | PA | View Drugs | View Results |
Aldesleukin | Proleukin | IL-2 receptor agonist | Approved in Other Cancers | Autologous TILs | | Immune response against tumor-associated antigens | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT03610490 | II | Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | TX | View Drugs | View Results |
MDA-TIL | autologous tumor-infiltrating lymphocytes MDA-TIL | Anti-tumor immune response | Clinical Trials |
|
|
| NCT02568267 | II | Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | AZ, CA, CO, FL, IL, MD, MA, MN, NV, NY, NC, OH, TX, UT, VA, WA | View Drugs | View Results |
Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04625270 | II | Recurrent low grade serous ovarian cancer with a KRAS mutation | A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | AZ, FL, MN, NY, OR, TX | View Drugs | View Results |
Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials | VS-6766 | CKI27, RO5126766, Raf/MEK dual kinase inhibitor RO5126766, CH5126766 | RAF and MEK inhibitor | Clinical Trials |
|
|
| NCT02873962 | II | Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor) | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | MA | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT01851369 | II | Granulosa cell ovarian cancer | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | MD | View Drugs | View Results |
Methoxyamine | TRC102 | Base excision repair inhibitor | Clinical Trials | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT02819843 | II | Advanced solid tumors - intratumoral injection | A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | NJ, NY | View Drugs | View Results |
Radiation Therapy | Radiotherapy, Irradiation | | | Talimogene laherparepvec | T-VEC, GM-CSF-encoding oncolytic herpes simplex virus | Induces immune response and tumor cell lysis | Approved in Other Cancers |
|
|
| NCT03697304 | II | Advanced solid tumors with prior anti-PD-1/PD-L1 Ab | An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy | CA, FL, IN, KY, OK, TN, WI | View Drugs | View Results |
BI 754111 | | Blocks LAG-3 inhibition of T cells | Clinical Trials | Ezabenlimab | anti-PD-1 monoclonal antibody BI 754091, BI 754091 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT04644315 | II | Advanced ALK+ solid tumors (excluding I1171X, G1202R, V1180L) | A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | CA | View Drugs | |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers |
|
|
| NCT02554812 | II | Advanced solid tumors (in ovarian expansion) - intratumoral injection | A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies | CA, DC, FL, IA, KY, MI, NY, PA, RI, SD, TX | View Drugs | |
Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | PD-0360324 | anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 | CSF1R antagonist and tumor-associated macrophage inhibitor | Clinical Trials |
|
|
| NCT02721732 | II | Recurrent germ cell, granulosa cell or small cell ovarian cancer | Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | TX | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04592653 | II | Recurrent ovarian cancer | Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3 | TX | View Drugs | View Results |
Nemvaleukin alfa | ALKS4230, Nemvaleukin, intermediate-affinity interleukin-2 receptor agonist ALKS 4230 | IL-2R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04171219 | II | Advanced solid tumors | A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers | TX | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Talabostat | BXCL701, Val-boro-Pro, talabostat mesylate, PT100 | Dipeptidyl peptidase inhibitor | Clinical Trials |
|
|
| NCT04449549 | II | Recurrent rare tumors | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02675829 | II | Advanced solid tumors with HER2 amplification | A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | NY | View Drugs | View Results |
Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT04729348 | II | Advanced solid tumors with leptomeningeal metastases | Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases | MA | View Drugs | |
Lenvatinib | E7080, ER-203492-00, Lenvima, MK-7902 | VEGFR1-3 kinase inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03872427 | II | Advanced solid tumors with NF1, KEAP1/NRF2 or LKB1 mutations | A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors | FL, KS, KY, MD, MA, MO, NY, NC, OH, PA, TX | View Drugs | View Results |
Telaglenastat | glutaminase inhibitor CB-839, CD-839 | Glutaminase inhibitor | Clinical Trials |
|
|
| NCT04753216 | II | Platinum resistant or refractory ovarian cancer | A Phase II Trial of Irinotecan Liposome and Bevacizumab in Women With Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | IL | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Liposomal irinotecan | Onivyde, MM-398, liposome-encapsulated irinotecan hydrochloride PEP02, nal-IRI, nanoliposomal irinotecan | Topoisomerase I inhibitor | |
|
|
| NCT04739618 | II | Advanced solid tumors - intratumoral injection | A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer | AZ | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Thermotherapy | | | Clinical Trials |
|
|
| NCT03637491 | II | Advanced solid tumors with KRAS and NRAS mutations, no prior avelumab | A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS | AR, CA, CO, IN, PA, TX, UT | View Drugs | View Results |
Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Binimetinib | MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi | MEK inhibitor | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT03428802 | II | Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | NJ | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03682289 | II | Advanced solid tumors with ARID1A (except clear cell) or ATM alterations | Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies | CA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04669002 | II | Primary platinum resistant high grade ovarian cancer with no prior bevacizumab and no prior PARP inhibitor or recurrent high grade ovarian cancer with at least 2 prior therapies and with prior PARP inhibitor maintenance | Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease & Are PARP Inhibitor naïve; Cohort 2 - Had at Least 2 Prior Lines of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance | FL, NY, TN, VA | View Drugs | View Results |
EP0057 | IT-101, cyclodextrin-based polymer-camptothecin CRLX101, camptothecin-polymer conjugate IT-101, CRLX101, NLG207 | Topoisomerase I inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04123366 | II | Advanced BRCA WT solid tumors with mutations in homologous repair (HRR) genes (i.e. BRIP1, PALB2) or HRD+ patients, no prior PARP inhibitor or checkpoint inhibitor | A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer | AL, AZ, CA, CO, FL, GA, KY, NJ, NY, OH, OK, TX, UT, VA, WA | View Drugs | View Results |
Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03742895 | II | Platinum resistant ovarian cancer without BRCA1/2 mutations, with Homologous Recombination Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+, no prior PARP inhibitor | A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer | AZ, CA, CO, GA, KY, MD, MA, MI, NE, NJ, NY, OK, PA, SD, UT, WA | View Drugs | View Results |
|
|
| NCT04589845 | II | Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMB | Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial | AL, CA, CO, DE, FL, GA, ID, IN, ME, MI, MN, MO, NV, NH, NJ, NM, NY, NC, OH, OR, PA, SC, TN, TX, WA, WI | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | GDC-0077 | RG6114 | PI3K alpha inhibitor | Clinical Trials | Idasanutlin | RO5503781, RG7388, MDM2 antagonist RO5503781 | MDM2 antagonist | | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT04632992 | II | Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, PIK3CA, PTEN, ROS1 or with high TMB or high MSI | MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | AZ, CA, CT, FL, LA, MI, MO, MT, NE, NJ, NY, OH, OR, TN, TX, WA | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | GDC-0077 | RG6114 | PI3K alpha inhibitor | Clinical Trials | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Approved in Other Cancers | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04692662 | II | Advanced solid tumors with alterations in ATM, BACH1 (BRIP1), BARD1, BRCA 1/2, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; gBRCA MUT patients must have progressed on prior PARP inhibitor) | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | MD | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04550494 | II | Platinum sensitive ovarian cancer with DDR gene alterations (only 1 prior platinum therapy; gBRCA MUT patients must have progressed on prior PARP inhibitor) | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | MD | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT03449108 | II | Recurrent high grade ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | TX | View Drugs | View Results |
Aldesleukin | Proleukin | IL-2 receptor agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | LN-145-S1 | Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapy | Immune response against tumor-associated antigens | Clinical Trials |
|